Biomarker predicts response to TNF blockers
A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2213 entries already.
A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
It’s the most commonly cultivated, trafficked and abused illicit drug worldwide, and there’s still a lot of social stigma attached to the recreational use of pot. But it’s slowly dawning on regulators in countries from Canada to the US to South Africa that by ignoring the clear medical benefits of marijuana, they may have thrown the baby out with the bathwater. Countries across Europe are now also opening their minds, laws and wallets to cannabis.
In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
Immunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discovery‘s antibody generation unit.
Swiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
The Innovative Medicines Initiative II has earmarked €80m for pre-competetive research improving the pharmaceutical industry’s productivity.
Novo Holdings has invested €18m from its €135m REPAIR Impact Fund into four companies.
According to a brand-new EU-wide survey, European plant researchers are concerned about the European Court of Justices (CJEU) interpretation that targeted mutation methods aimed at improving crop yield and resistance to climate change yield GMOs. In an open letter, they call for political action and a modernisation of the EU Directive 2001/18/EC because a lack in tech-transfer would put Europe at the bottom of the pile in the upcoming bioeconomy.
Boehringer Ingelheim has expanded its 2014 R&D collaboration with the BioMed X Innovation Center (Heidelberg, Germany) to find new treatment approaches for early intervention of psychiatric diseases.
Canadian and Finnish researchers have demonstrated that long immune cell contact to lung tissue turns tissue repair into fibrosis.

